BioNexus Gene Lab Corp（BGLC）資訊與事件BGLCBioNexus Gene Lab Corp

Ruanyun Edai Technology Signs Exclusive License Agreement with BioNexus

Ruanyun Edai Technology (RYET) announced that it has signed a definitive agreement under which, on closing, Ruanyun Edai Technology would grant BioNexus Gene Lab (BGLC) an exclusive license of its Cogni AI document-intelligence platform for healthcare in Malaysia, together with a reciprocal share exchange. The agreement would take Cogni AI into a new industry and a new market outside China. Ruanyun would be entitled to a 10% royalty on qualifying technology receipts collected by BGLC and its affiliates and would receive 560,000 BGLC shares at closing, 150,000 of them in exchange for 500,000 new RYET ordinary shares, giving it a direct stake in the partner that would take its technology to market.

BioNexus Gene Lab Appoints Dr. Muthu Meyyappan as Chief Commercial Officer

BioNexus Gene Lab announced that, in connection with its Fidelion Diagnostics transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Dr. Meyyappan will lead Fidelion's global commercial strategy and partnerships, including the development of clinical, laboratory, and pharmaceutical collaborations to support the adoption of advanced oncology diagnostic technologies across international markets. Most recently, Dr. Meyyappan served as CCO at Menarini Silicon Biosystems, where he helped expand the company's oncology diagnostics business and supported the commercial adoption of liquid biopsy and MRD-related diagnostic platforms.

BioNexus Completes Governance Restructuring of Chemrex Corporation

BioNexus Gene Lab announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation. As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew Barsing, Chairman; Angeline Chong, Chief Financial Officer of BioNexus, Director. New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates under the oversight framework of the BioNexus Board of Directors and its committees.